Stifel analyst Adam Walsh upgraded Protagonist Therapeutics (NASDAQ: PTGX) from Hold to Buy with a price target of $17.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE